86265-88-5 Usage
Uses
3-BROMO-4-CHLORO-BENZALDEHYDE can be used as organic synthesis intermediate and pharmaceutical intermediate, mainly used in laboratory research and development process and chemical production process.
Synthesis
The product from above (3.4 g, 22 mmol) in concentrated 48% aqueous HBr (20 mL) at 0 °C was treated with a 0 °C solution of NaNO2 (1.5 g, 22 mmol) in water (30 mL). The reaction mixture was stirred for 30 min and then transferred cold to a stirred solution of CuBr (4.44 g, 31 mmol) in 48% aqueous HBr (20 mL) at 23 °C (significant frothing!). Water (40 mL) was added, the solution was heated at 60 °C for 45 min, cooled, diluted with EtOAc (200 mL) and water (50 mL), and the layers were separated. The aqueous layer was extracted with EtOAc (2x, 50 mL). The organic layers were combined, washed with 1 M HCl (2x, 100 mL) and brine (50 mL), dried (Na2SO4), filtered, and concentrated to provide 3-bromo-4-chlorobenzaldehyde as a pale yellow powder (3.9 g, 82%). 3-Bromo-4-chlorobenzaldehyde, yield 3.9 g, 82%
Check Digit Verification of cas no
The CAS Registry Mumber 86265-88-5 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 8,6,2,6 and 5 respectively; the second part has 2 digits, 8 and 8 respectively.
Calculate Digit Verification of CAS Registry Number 86265-88:
(7*8)+(6*6)+(5*2)+(4*6)+(3*5)+(2*8)+(1*8)=165
165 % 10 = 5
So 86265-88-5 is a valid CAS Registry Number.
InChI:InChI=1S/C7H4BrClO/c8-6-3-5(4-10)1-2-7(6)9/h1-4H
86265-88-5Relevant articles and documents
Substituted biaryl compounds as factor XIa inhibitors
-
Page/Page column 29, (2008/06/13)
The present invention provides compounds of Formula (I): or a stereoisomer, tautomer, pharmaceutically acceptable salt or solvate form thereof, wherein the variables A, L, Z, R3, and ring B are as defined herein. The compounds of Formula (I) ar
Oxime derivatives for the treatment of dyslipidemia and hypercholesteremia
-
, (2008/06/13)
The present invention relates to compounds of Formula (I) which may be useful in the treatment of diseases, such as, metabolic disorders, dyslipidemia and/or hyperchloesterolemia: 1
CALCIUM RECEPTOR MODULATING ARYLALKYLAMINES
-
Page 63, (2008/06/13)
The compounds of the invention are represented by the following general structure (I) or a pharmaceutically acceptable salt thereof, and compositions containing them, wherein the variables are defined herein, and their use to reduce or inhibit PTH secretion, including methods for reducing or inhibiting PTH secretion and methods for treatment or prophylaxis of diseases associated with bone disorders, such as osteoporosis, or associated with excessive secretion of PTH, such as hyperparathyroidism. The subject invention also relates to processes for making such compounds as well as to intermediates useful in such processes.
